Impaired insulin clearance in essential hypertension

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The purpose of this study was to examine whether impaired insulin clearance contributes to the hyperinsulinemia observed in humans with essential hypertension. Previous studies from our group and others have demonstrated that individuals with essential hypertension are resistant to the glucoregulatory effect of insulin. Animal models have confirmed this finding and have suggested that hypertensive animals have impaired insulin clearance that might contribute to the observed hyperinsulinemia. The metabolic clearance rate of insulin (MCR(ins)) was calculated during a constant infusion of glucose (320 mg/m2/min) and insulin (25 mU/m2/min), under conditions where endogenous insulin secretion was suppressed by somatostatin infusion (250 μg/h) for four groups of age sex and weight-matched patients: normotensive volunteers, untreated hypertensives, hypertensives treated with diuretics and hypertensives treated with diuretics and beta-blockers. MCR(ins) was impaired in all three groups of hypertensive subjects compared with normal BP volunteers, particularly in untreated hypertensives and those treated with combination diuretic and beta-blocker therapy: normal = 0.6 ± 0.1; untreated = 0.47 ± 0.2; diuretic = 0.51 ± 0.1; combination = 0.39 ± 0.2 (in ml/min, expressed as mean ± SD). The effectiveness of somatostatin for islet suppression was confirmed by demonstrating markedly diminished C-peptide concentrations in untreated hypertensives and normal volunteers. Thus, our previous finding of elevated steady-state plasma insulin during insulin suppression testing in hypertensives seems not to be the result of impaired pancreatic response to somatostatin but, rather, there seems to be a defect in insulin clearance in these individuals not unlike that demonstrated in animal models of hypertension and insulin resistance. The nature of this defect remains to be elucidated.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalJournal of Human Hypertension
Volume8
Issue number3
StatePublished - 1994
Externally publishedYes

Fingerprint

Insulin
Diuretics
Somatostatin
Metabolic Clearance Rate
Hyperinsulinism
Healthy Volunteers
Animal Models
Essential Hypertension
C-Peptide
Insulin Resistance
Volunteers
Age Groups
Hypertension
Weights and Measures
Glucose

Keywords

  • Hyperinsulinaemia
  • Hypertension
  • Insulin clearance

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Impaired insulin clearance in essential hypertension. / Swislocki, Arthur L.

In: Journal of Human Hypertension, Vol. 8, No. 3, 1994, p. 185-190.

Research output: Contribution to journalArticle

@article{ae2f535c369444e8aa4ef907ebdec3a1,
title = "Impaired insulin clearance in essential hypertension",
abstract = "The purpose of this study was to examine whether impaired insulin clearance contributes to the hyperinsulinemia observed in humans with essential hypertension. Previous studies from our group and others have demonstrated that individuals with essential hypertension are resistant to the glucoregulatory effect of insulin. Animal models have confirmed this finding and have suggested that hypertensive animals have impaired insulin clearance that might contribute to the observed hyperinsulinemia. The metabolic clearance rate of insulin (MCR(ins)) was calculated during a constant infusion of glucose (320 mg/m2/min) and insulin (25 mU/m2/min), under conditions where endogenous insulin secretion was suppressed by somatostatin infusion (250 μg/h) for four groups of age sex and weight-matched patients: normotensive volunteers, untreated hypertensives, hypertensives treated with diuretics and hypertensives treated with diuretics and beta-blockers. MCR(ins) was impaired in all three groups of hypertensive subjects compared with normal BP volunteers, particularly in untreated hypertensives and those treated with combination diuretic and beta-blocker therapy: normal = 0.6 ± 0.1; untreated = 0.47 ± 0.2; diuretic = 0.51 ± 0.1; combination = 0.39 ± 0.2 (in ml/min, expressed as mean ± SD). The effectiveness of somatostatin for islet suppression was confirmed by demonstrating markedly diminished C-peptide concentrations in untreated hypertensives and normal volunteers. Thus, our previous finding of elevated steady-state plasma insulin during insulin suppression testing in hypertensives seems not to be the result of impaired pancreatic response to somatostatin but, rather, there seems to be a defect in insulin clearance in these individuals not unlike that demonstrated in animal models of hypertension and insulin resistance. The nature of this defect remains to be elucidated.",
keywords = "Hyperinsulinaemia, Hypertension, Insulin clearance",
author = "Swislocki, {Arthur L}",
year = "1994",
language = "English (US)",
volume = "8",
pages = "185--190",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Impaired insulin clearance in essential hypertension

AU - Swislocki, Arthur L

PY - 1994

Y1 - 1994

N2 - The purpose of this study was to examine whether impaired insulin clearance contributes to the hyperinsulinemia observed in humans with essential hypertension. Previous studies from our group and others have demonstrated that individuals with essential hypertension are resistant to the glucoregulatory effect of insulin. Animal models have confirmed this finding and have suggested that hypertensive animals have impaired insulin clearance that might contribute to the observed hyperinsulinemia. The metabolic clearance rate of insulin (MCR(ins)) was calculated during a constant infusion of glucose (320 mg/m2/min) and insulin (25 mU/m2/min), under conditions where endogenous insulin secretion was suppressed by somatostatin infusion (250 μg/h) for four groups of age sex and weight-matched patients: normotensive volunteers, untreated hypertensives, hypertensives treated with diuretics and hypertensives treated with diuretics and beta-blockers. MCR(ins) was impaired in all three groups of hypertensive subjects compared with normal BP volunteers, particularly in untreated hypertensives and those treated with combination diuretic and beta-blocker therapy: normal = 0.6 ± 0.1; untreated = 0.47 ± 0.2; diuretic = 0.51 ± 0.1; combination = 0.39 ± 0.2 (in ml/min, expressed as mean ± SD). The effectiveness of somatostatin for islet suppression was confirmed by demonstrating markedly diminished C-peptide concentrations in untreated hypertensives and normal volunteers. Thus, our previous finding of elevated steady-state plasma insulin during insulin suppression testing in hypertensives seems not to be the result of impaired pancreatic response to somatostatin but, rather, there seems to be a defect in insulin clearance in these individuals not unlike that demonstrated in animal models of hypertension and insulin resistance. The nature of this defect remains to be elucidated.

AB - The purpose of this study was to examine whether impaired insulin clearance contributes to the hyperinsulinemia observed in humans with essential hypertension. Previous studies from our group and others have demonstrated that individuals with essential hypertension are resistant to the glucoregulatory effect of insulin. Animal models have confirmed this finding and have suggested that hypertensive animals have impaired insulin clearance that might contribute to the observed hyperinsulinemia. The metabolic clearance rate of insulin (MCR(ins)) was calculated during a constant infusion of glucose (320 mg/m2/min) and insulin (25 mU/m2/min), under conditions where endogenous insulin secretion was suppressed by somatostatin infusion (250 μg/h) for four groups of age sex and weight-matched patients: normotensive volunteers, untreated hypertensives, hypertensives treated with diuretics and hypertensives treated with diuretics and beta-blockers. MCR(ins) was impaired in all three groups of hypertensive subjects compared with normal BP volunteers, particularly in untreated hypertensives and those treated with combination diuretic and beta-blocker therapy: normal = 0.6 ± 0.1; untreated = 0.47 ± 0.2; diuretic = 0.51 ± 0.1; combination = 0.39 ± 0.2 (in ml/min, expressed as mean ± SD). The effectiveness of somatostatin for islet suppression was confirmed by demonstrating markedly diminished C-peptide concentrations in untreated hypertensives and normal volunteers. Thus, our previous finding of elevated steady-state plasma insulin during insulin suppression testing in hypertensives seems not to be the result of impaired pancreatic response to somatostatin but, rather, there seems to be a defect in insulin clearance in these individuals not unlike that demonstrated in animal models of hypertension and insulin resistance. The nature of this defect remains to be elucidated.

KW - Hyperinsulinaemia

KW - Hypertension

KW - Insulin clearance

UR - http://www.scopus.com/inward/record.url?scp=0028202135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028202135&partnerID=8YFLogxK

M3 - Article

C2 - 7911838

AN - SCOPUS:0028202135

VL - 8

SP - 185

EP - 190

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 3

ER -